1-13 of 13
Keywords: Parkinson's disease
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Clin Sci (Lond) (2022) 136 (13): 1071–1079.
Published: 11 July 2022
...Susanne Herbst; Patrick A. Lewis; Huw R. Morris Parkinson’s disease (PD) is conventionally described as an α-synuclein aggregation disorder, defined by Lewy bodies and neurites, and mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common autosomal dominant cause of PD. However, LRRK2...
Articles
Articles
Articles
Articles
Clin Sci (Lond) (2011) 120 (10): 427–440.
Published: 28 January 2011
... in any medium, provided the original work is properly cited. aging Alzheimer's disease atherosclerosis heart failure longevity Parkinson's disease telomerase telomere The 2009 Nobel Prize in Physiology or Medicine was awarded jointly to Dr Elizabeth H. Blackburn, Dr Carol W. Greider...
Articles
Articles
Clin Sci (Lond) (2005) 109 (4): 343–354.
Published: 23 September 2005
... to the diagnosis and management is emphasized. Correspondence: Dr Bradley F. Boeve (email bboeve@mayo.edu ). 17 3 2005 13 4 2005 The Biochemical Society 2005 dementia with Lewy bodies (DLB) genetic basis Lewy body disease Parkinson's disease Friederich Lewy in the early...
Articles
Clin Sci (Lond) (2005) 109 (4): 355–364.
Published: 23 September 2005
...Shushant Jain; Nicholas W. Wood; Daniel G. Healy Major progress has been made in the last decade in understanding the genetic basis of PD (Parkinson's disease) with five genes unequivocally associated with disease. As a result, multiple pathways have been implicated in the pathogenesis of PD...
Articles
Clin Sci (Lond) (1994) 86 (2): 149–158.
Published: 01 February 1994
... linked either pharmacologically or biochemically to central noradrenergic neuronal activity. 4. Cerebrospinal fluid dopamine β-hydroxylase was not changed in essential hypertension. In Parkinson's disease, cerebrospinal fluid dopamine β-hydroxylase was markedly diminished (16.3 ± 2.9 versus 31.3 ± 1.4 ng...
Articles
Articles
Clin Sci (Lond) (1979) 56 (1): 89–93.
Published: 01 January 1979
...D. A. Bender; C. J. Earl; A. J. Lees 1. Benserazide and carbidopa, decarboxylase inhibitors used in the treatment of Parkinson's disease, have been shown to inhibit the enzyme kynurenine hydrolase in rat and mouse liver. This results in reduced synthesis of nicotinamide coenzymes from tryptophan...
Articles
Clin Sci Mol Med (1977) 53 (4): 321–328.
Published: 01 October 1977
...C. S. Wilcox; M. J. Aminoff; J. D. H. Slater 1. The renal excretion of sodium by five patients with autonomic failure (Shy—Drager syndrome) was compared with a matched control group who had normal autonomic reflexes (Parkinson's disease). For 8 or 9 days the daily sodium intake was reduced to 17...
Articles
Clin Sci Mol Med (1974) 46 (4): 481–488.
Published: 01 April 1974
...C. S. Wilcox; M. J. Aminoff; A. B. Kurtz; J. D. H. Slater 1. The effect on plasma renin activity (PRA) of dopamine and noradrenaline infusions was studied in three patients with Shy—Drager syndrome, three patients with Parkinson's disease and normal autonomic reflexes, and three healthy volunteers...